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Plasma is a rich mine of various biomarkers including proteins, metabolites and circulating nucleic acids.
The diagnostic and therapeutic potential of these analytes has been quite recently uncovered, and the
number of plasma biomarkers will still be growing in the coming years. A significant part of the blood
plasma preparation is still handled manually, off-chip, via centrifugation or filtration. These batch methods
have variable waiting times, and are often performed under non-reproducible conditions that may impair
the collection of analytes of interest, with variable degradation. The development of miniaturised modules
capable of automated and reproducible blood plasma separation would aid in the translation of lab-on-a-
chip devices to the clinical market. Here we propose a systematic review of major plasma analytes and
target applications, alongside existing solutions for micro-scale blood plasma extraction, focusing on the
approaches that have been biologically validated for specific applications.
1. Introduction
Despite all the recent advances made in the lab-on-a-chip field,
sample preparation remains a major technical hurdle in the
path of large scale commercialization and public access to
point-of-care (POC) biomedical devices. With very few excep-
tions, such as the pregnancy test from a urine sample or
glucose measurement from blood, sample preparation comes
with any diagnostic or analysis, and has been branded ‘‘the
weak link in microfluidics-based biodetection’’.1 Mariella
proposes several reasons for the lack of interest in on-chip
sample preparation. The first reason is economical, as the
emerging microfluidic field has not triggered enough real
commercial possibilities for sample preparation to be devel-
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oped. Moreover, microfluidic technologies do not yet compete
technically and cost-effectively with existing techniques;
macroscale centrifugation remains just as simple, efficient
and cheap. Another reason, more social, is the ‘‘inertia’’ of the
current techniques and the lack of will for trained staff to
change their traditional protocols. Last but not least, the
integration of sample preparation is a challenging technical
problem in itself. Sometimes referred to as the world-to-chip
issue,2 the issue even has a dedicated yearly conference
‘‘Integrating Sample Preparation’’ which has been running for
6 years. The integration of sample preparation is complicated
by various factors including the complexity of sample matrices
and the use of disparate material between sample preparation
and detection units, which may lead to leakage problems.
These difficulties have deterred engineers and researchers
from developing adapted sample preparation solutions in the
first place, and the focus has been shifted towards other
functionalities, such as detection. A lack of generic automated
and integrated solutions for sample preparation means that
most processes are still performed in macroscale tubes on the
bench, potentially introducing human errors.
Several reviews have targeted the challenges of sample
preparation and its integration, including blood samples in
particular.1,3–5 The complexity of the blood matrix is generally
pointed out as the major hurdle towards on-chip blood
preparation. Although very smart and precise tools have been
developed, the main focus seemed to be on the demonstration
of functionalities other than sample preparation, notably on
the analysis and transduction of a chemical or physical
detection into a readable electronic signal. Indeed, most of
the prototypes developed have been mainly focused on
analytical sensitivity and how it compares to conventional
techniques. Although a few commercial examples with
integrated sample preparation are available, such as (i)
Cholestech measuring aspartate and alanine aminotransferase
for hepatic diagnostic, (ii) CoaguChek monitoring prothrom-
bin time during anticoagulation therapy, or (iii) the BioSite
chip for the detection of three proteins linked to stroke
pathologies, blood sample preparation has been more rarely
considered and fully integrated on-chip. It is worth mention-
ing that these examples detect the presence of plasma analytes
at high concentration, with the capacity for capillary-scale
volumes for facile detection. Besides these specific examples, a
significant part of the blood preparation is still handled
manually, off-chip, with variable waiting time, and under non-
reproducible conditions that may impair the collection of
analytes of interest. The lack of suitable devices to perform
such preparation at the microscale is the bottleneck towards
complete integration of blood analysis. Furthermore, the
development of miniaturised modules capable of automated
Table 1 Lexicon of biological terms and acronyms used in this review
Term Definition
Dilution ratio Ratio of the unit volumes of blood over the total volume of sample after dilution. In most cases, diluent is Phosphate
Buffered Saline (PBS).
Erythrocytes -
RBCs
Most common type of blood cell, accounting for 98% of blood cells, at a concentration of 5 6 106 per mL of blood.
Responsible for the transport of oxygen in blood. Erythrocytes are 7–8 mm large and have a discoid shape. Also known
as red blood cells (RBCs).
Extraction rate Flow rate at the plasma outlet in an experimental microfluidic set-up.
Hematocrit - Hct Volume percentage of RBCs in blood. This value depends on the age and health of the patient. Approximated at 40–
50% for healthy patients.
Leukocytes -
WBCs
Account for 1% of the total blood cells, at a concentration of 4–10 6 103 per mL of blood, with sizes varying from 7 to
30 mm. Leukocytes play a major role in the immune response. Also known as white blood cells (WBCs).
Plasma Liquid phase of the blood. Supernatant collected after centrifugation of a blood sample in which anticoagulant was added.
Plasma contains fibrinogen and other clotting proteins.
Purity Purity relates to the number of RBCs remaining in the plasma extracted. In this review it is defined as a percentage by:
1{
cp
cf
Where cp is the number of RBCs in the plasma fraction and cf is the number of RBCs in the feed (inlet) fraction;
e.g.: 100% purity means no cells were detected in the plasma fraction.
Serum Supernatant collected after centrifugation of a blood sample in which no anticoagulant was added.
Thrombocytes -
PLTs
Account for 1% of the total blood cells, at a concentration of 150–400 6 103 per mL of blood. 2–4 mm in size. Small cells
responsible for clot formation in blood and the coagulation process. Also known as platelets (PLTs).
Yield The percentage of extracted plasma volume over the total volume of blood injected.
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and reproducible blood separation would certainly aid in the
translation of blood-related lab-on-a-chip devices to the
clinical market.
Despite being overlooked in many studies and labs-on-
chips, the separation of plasma from blood is a requirement in
many medical diagnostic procedures. Plasma is a straw-
colored liquid and accounts for around 55% of total blood
volume. It must not be confused with serum, which is the
supernatant before anticoagulants have been added to the
blood (Table 1). Most of the examples detailed in this review
consider plasma, unless otherwise specified. Plasma is an
aqueous substance, made out of 95% water, and is host to a
myriad of analytes including proteins, metabolites, circulating
nucleic acids (CNAs) and other organisms. The efficient
detection of these analytes requires plasma to be completely
free of cells, thereby reducing the pollution of contaminants,
which might otherwise interfere with the accuracy of analyses.
The diagnostic and prognostic potential of plasma analytes
was recently uncovered6,7 and has fuelled the research into
miniaturised blood plasma separation (Fig. 1). For example,
CNAs have been found to be of great utility for the diagnosis or
prognosis of multiple cancers,8 malaria9 and stroke.10 CNAs
are also used for the monitoring of pregnancies and
transplantations.7 Similarly, various proteins have been
accepted as biomarkers for the diagnosis of several cancers.11
The LOC community has recognised that the lack of
convenient solutions for blood plasma separation does not
match the possible breadth of applications. Thus, there has
been a steady growth in the number of publications about
blood plasma separation by microfluidics from 2005 onwards
and an exponential growth in the number of citations of the
subject (Fig. 1). New ways to diagnose and treat a patient are
emerging and may lead to further opportunities for microscale
blood plasma separation. For example, blood plasma separa-
tion is particularly relevant in the field of theranostics, or
companion diagnostics, the new driver for bed-side diagnosis
and treatment. Theranostics is defined as the combination of
the diagnostic and therapeutic fields, whereby a disease could
be screened daily, and is expected to reach a market worth
$19.3 billion by 2023.12 Therefore it becomes necessary to get
blood samples from patients one or more times each day.
Microfluidics is particularly helpful in that respect, as it
permits the analysis of a few microlitres of biological sample
and avoids painful blood extraction of several dozens of
millilitres.
Recent reviews have already assessed microscale methods
for continuous particle separation or sample preparation
issues.1,5,13,14 In this article, we focus mainly on microscale
blood plasma extraction solutions. This paper does not intend
to give a historical review of the subject, but rather provides a
critical review of the recent advances in the field as well as
their applications. To achieve this purpose, the second part of
this review assesses the analytes and biomarkers of interest in
plasma and associated pathologies. The third part is focused
on the challenges specific to blood plasma separation. The
fourth part and core of the review is dedicated to the
technological solutions currently available, which are divided
into three formats: the chip format, the CD format, and the
paper format. In this section, we will compare the different
techniques and devices based on their performances such as
purity, yield, and capacity to be integrated with analytical
modules. In this purpose, a lexicon of the principal technical
terms used in this review is available in Table 1. Subsequently,
we will also discuss how these devices have been exploited for
various applications and conclude by highlighting the possible
future directions for blood plasma separation on-chip.
2. Plasma analytes and diagnostic
applications
Plasma, a water-based biological buffer, constitutes more than
50% of the blood volume in most mammals including
humans. Plasma can be rich with indicators of various
Fig. 1 Graphs representing (top) the number of citations per year and (bottom)
the number of publications between 1993 and 2012. These results were compiled
using Thomson Reuters citation database on the ‘‘Web of Science’’ website using
the key words ‘‘blood’’, ‘‘plasma’’, ‘‘separation’’ and ‘‘microfluidic’’. While these
results do not reflect exactly the number of publications in the field of microscale
blood plasma separation, it gives a clear indication of the growing interest generated
by the field.
This journal is  The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 3323–3346 | 3325
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diseases, which is why separating plasma from blood is of
clinical importance. Plasma hosts many components, includ-
ing but not limited to proteins, molecules, microorganisms or
circulating nucleic acids, whose relative concentrations are
indicated in Fig. 2. In this section we will detail a few of these
useful biomarkers and their associated diagnostic applica-
tions.
2.1. Circulating nucleic acids
Circulating Nucleic Acids, or CNAs, are nucleic acids floating
freely in human blood and other body fluids. CNAs include
fragmented DNA and RNA, as well as microRNA. Although
their origin is still obscure, they can be differentiated between
cell-free (cf) nucleic acids and cell-associated (ca) nucleic
acids.15 At the time of their discovery in 1948 by Mandel and
Metais, they were not directly associated with pathologies.16 It
was only 30 years later, in 1977, that CNAs were associated
with a pathology in lung cancer patients.17 More recently,
elevated levels of CNAs have been linked to various pathologies
and emerged as potential biomarkers.18 While in healthy
individuals, cfDNA concentration in blood ranges between 0
and 100 ng mL21 with a mean value of 30 ng mL21,19 cancer
patients have higher levels of cfDNA usually around 180 ng
mL21. The release mechanisms of CNAs is thought to originate
mostly from cell apoptosis.8 To support this hypothesis, CNA
levels were demonstrated to drop by up to 90% after
radiotherapy in several types of cancer, while more moderate
drops (below 63%) have been reported in other cancers.20
Thus, CNAs may be used as a theranostic tool when assessing
treatment effectiveness in patients affected by malignant
tumors.
Elevated levels of cell-free DNA have also been detected in
patients suffering from malaria and are suspected of playing a
role in malaria-induced inflammation.21 The monitoring of
CNA levels could be used for the diagnosis and prognosis of
this disease, along with a better clinical management in
affected zones.9 Donor CNAs have been found in the plasma of
hosts after organ transplantation and are described as a
naturally occurring microchimerism (i.e. the presence in a
small quantity of foreign genomic information in a person).
Therefore they may also be used as rejection markers for the
monitoring of graft versus host disease after transplantation.22
Another application of CNAs lies in Non-Invasive Diagnosis
or Testing (NIPD or NIPT). Traditionally, methods to sample
fetal material for prenatal diagnosis, like amniocentesis or
chorionic villus sampling (CVS), are invasive with associated
risks including bleeding, leakage, and foetal miscarriage.
Amniocentesis leads to miscarriage in approximately 1% of
cases and CVS in around 1–2% of cases.23,24 These percentages
are quite significant as around 200 000 amniocenteses are
conducted in the US each year, while 20 000 amniocenteses
and 5200 CVS occur every year in the UK alone. These
procedures can also have undesirable collateral effects, such
as infection to the mother or the foetus. Since their discovery
in 1997,25 numerous studies have demonstrated the existence
of cell free fetal nucleic acids (cffNAs) in maternal circulation.
This flow of genetic information provides a unique opportu-
nity for the development of techniques for NIPT. cffNA is
routinely used today to diagnose gender-linked conditions26 or
fetal rhesus D status and has also been demonstrated to be a
potential indicator for pregnancy associated diseases such as
pre-eclampsia and preterm labour.
Furthermore, CNAs have been put forward as biomarkers for
auto-immune diseases, such as rheumatoid arthritis or
systemic sclerosis, where the high levels of CNAs correlate
with the intensity of the disease.7 In other diseases which lead
to rapid cell death, such as trauma, sepsis, or cardio-vascular
accidents, elevated CNA levels have been reported and may be
used as prognostic markers to judge the efficacy of a treatment
and the severity of the injury.7
In this section, we have cited a few of the possible
applications of CNAs found in blood plasma. A recent and
exhaustive review of the subject can be found in ref. 7. The
excitement around CNAs largely originates from the possibility
they offer to bypass invasive procedures in the diagnosis of
life-threatening tumors and genetic conditions for prenatal
testing. Analysis of CNAs first requires the separation of
plasma or serum from whole blood. Another advantage of
CNAs is their rapid clearance from the body, which minimises
carry-over contamination. Studies have shown that fetal DNA
found in maternal circulation is cleared out 20 min after the
Fig. 2 Blood composition. Plasma is host to a myriad of components, most of
which have diagnostic and therapeutic potential. Nucleic acid levels are from
ref. 18 and metabolite concentrations from ref. 6.
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birth,27 which means that CNA detection is not susceptible to
false-positives which would result from earlier pregnancies.
2.2. Proteins
Proteins play a predominant part in most biological processes.
Studying proteins may give clues about the health of cells as
evidenced in oncological studies.28 Sampling blood is a less
invasive approach to detect and monitor cancer without
having to subject patients to clinical interventions such as
biopsies. Instead of studying the primary tumor, cancer can
now be characterized at the molecular level not only by DNA
copy number analysis or patterns in gene expressions, but also
by changes in serum proteins. Cancer-associated proteins may
be used not only to detect cancer tumors at an early stage of
development but also to monitor its progression and response
to therapy.29 In a relatively recent catalogue, 22% of 1261
proteins proposed as cancer biomarkers were traced in
plasma.11 Among the most common protein cancer biomar-
kers, Prostate-Specific Antigen (PSA) detection has been widely
used as a screening test for prostate cancer, both in clinical
settings30 and as an application for lab-on-a-chip devices.31,32
As another protein example, a group of plasma proteins
called transaminases, including aspartate aminotransferase
(AST) and alanine aminotransferase (ALT), are routinely used
to study the hepatic (or liver) functions. The detection of ALT
and AST in serum has been demonstrated on-chip in several
formats.33 Although no plasma or serum extraction steps were
integrated in this example, a more recent example from
Whitesides’ group includes plasma filtration and transami-
nase analysis in a paper format.34 An exhaustive review of AST/
ALT detection techniques can be found in ref. 35. C-Reactive
protein or CRP is another plasma protein widely used as a non-
specific marker for the acute phase during an inflammation.36
While normal CRP levels in healthy individuals are reported to
be less than 10 mg L21, these can rise up to 350–400 mg L21 in
a number of pathologies, including appendicitis and pelvic
inflammatory disease. As a non-specific marker, CRP is not
recommended for diagnostic purposes but may be used to
indicate failure of an antibiotic treatment.36,37 However,
because of the large number of methods available for its
rapid and precise quantification, CRP detection is still an
appealing technique for clinicians and has consequently been
largely applied in lab-on-a-chip devices.38–40 Aota et al.
proposed for example a passive plasma separation device
and validated it with microELISA analysis of CRP levels.40 A
blood filtering membrane was also proposed in conjunction
with a protein capture strategy to detect CRP levels.41 However,
the device was loaded directly with human serum instead of
whole blood.
Proteins can also be used to monitor pregnancy, as
pregnancy-related proteins are present in the plasma of
expectant mothers. Human Chorionic Gonadotrophin (hCG)
protein is a hormone produced during pregnancy. hCG levels
are undetectable in non-pregnant women but double every two
days during early pregnancy. A blood hCG test is required to
confirm whether a woman is pregnant, but hCG levels are also
monitored for prenatal diagnosis.42 A number of other
markers including Pregnancy-Associated Plasma Protein A
(PAPPA)43 and pregnancy specific b1-glycoprotein (SP1)44 can
be assessed, in the latter case for the detection of Trisomy 18
or Edwards Syndrome, a serious chromosomal abnormality.
Finally, sepsis, or inflammatory response, is often asso-
ciated with elevated levels of proteins.45 Plasma proteins are
also used to continuously monitor inflammatory response
during surgeries, such as cardiopulmonary surgery.46 In this
case, the lengthy separation time (during which the operation
may last several hours) is a challenge that will require specific
approaches with non-clogging systems, as demonstrated in a
microfluidic format in ref. 46.
Protein analysis is widely used in clinical settings to
diagnose various diseases or monitor treatment effectiveness
in patients. As some of these proteins are available in high
concentrations in blood, most of the applications presented in
this section are compatible with plasma or serum extraction
on chip or paper formats dealing with capillary volumes.
2.3. Metabolites
The Human Serum Metabolome project was set-up recently to
develop a database of metabolites found in biological fluids,
including serum or plasma.6 Metabolites are a group of small
molecules including amino-acids, sugars and fats. Five of the
most abundant organic metabolites found in serum are
glucose (5 mM), total cholesterol (5 mM), melanin (5 mM),
urea (4 mM), and adenosine triphosphate ATP (3 mM) (out of
more than 4000 catalogued in ref. 6). Analysis of multiple
metabolites in the bloodstream can be used to create a patient
metabolic fingerprint or signature that could help to assess
health status at any given time.
Glucose, or blood sugar, measurement is widely used to
monitor medical conditions including diabetes. Serum glu-
cose levels are favored over whole blood glucose levels as the
variation of hematocrit may influence the results.47 The reason
behind this variability lies in the higher dissolution rate of
glucose in serum. However, most POC devices still measure
glucose levels in whole blood, which has cast a doubt over
their reliability47,48 and which might necessitate restriction of
use of POC devices with patients having a normal hematocrit
level.49 Glucose measurements have been widely developed in
LOC microfluidic formats,50–52 as well as LOC paper format.53
However, more devices should integrate a blood plasma
extraction step, for the reasons detailed above. The detection
of cholesterol, the second most abundant metabolite in blood,
has also been demonstrated in various chip formats. The
majority of them focus on electrochemical detection and few
integrate a blood plasma extraction step.54,55 In ref. 56
however, Sun et al. proposed a technique using a disposable
length of tubing to extract 60% of plasma from 1 mL of blood
and characterised the extracted plasma with a cholesterol
colorimetric test. ATP, the cellular energy carrier, has also
been detected on-chip but without sample preparation and
sometimes in urine samples rather than serum or plasma.57,58
Several hormones may be of interest for lab-on-a-chip
detection, including thyrotropin (TSH) or thyroxine (T4),
involved in the detection of diseases linked to thyroid
function. A microchip using electrophoresis was developed
to perform T4 detection on serum.59 Testosterone and
estradiol, respectively the male and female sex hormones,
may be used to diagnose ageing-related issues.60 While some
This journal is  The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 3323–3346 | 3327
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hormones were detected in a lab-on-a-chip format,61 few of
these analyses were done directly on blood. One example
introduced the detection of progesterone from bovine serum,
but did not integrate sample treatment in the device.62
Blood glucose and other metabolites are in concentrations
high enough (4–8 mM for blood glucose in healthy adult) to be
compatible with capillary volumes on the scale of a finger-
prick blood droplet. These metabolic applications have been
quite extensively demonstrated on-chip, however most exam-
ples failed to include blood plasma extraction, which renders
such devices reliant on conventional centrifugation.
2.4. Viruses
Viruses are ubiquitous and can be transmitted via various
routes, such as droplet transmission, direct or sexual contact,
or even contaminated food and water, and may consequently
cause worldwide outbreaks.63 According to the Bill & Melinda
Gates Foundation, enteric viruses, dengue and yellow fever,
HIV, viruses causing influenza, and pneumonia are considered
the leading causes of childhood deaths, especially in the
developing world.64,65 These viruses are now priority areas of
focus66 for the global health community to tackle the lack of
effective, fast, and cheap diagnostics and enable earlier
detection of infections and prevention of pandemics. Viruses
are also an established cause of cancer; for example, the
human papilloma virus is known to cause cancers of the
cervix, skin, anus, and penis.
Viral diagnostics involve various kinds of biological sam-
ples, such as urine and saliva,67 but blood is the sample of
choice for the detection of viral pathogens like HIV or Epstein–
Barr virus among others.68,69 In blood, viral particles (20–400
nm) are surrounded by larger bacteria (300 nm to 10 mm) and
cells (10 to 100 mm), which makes their detection a challenge
in terms of sensitivity and specificity. Importantly, the viral
concentration in samples is usually low, with only 102–106 HIV
virions per mL of plasma.70 In effect, to avoid blood cell
contamination, many laboratories process blood samples off-
chip to directly detect viruses like HIV or dengue from plasma
or serum.64,70,71
Schulze et al.72 and Cheng et al.73 have presented many
recent integrated devices for molecular viral detection (anti-
genic and genomic), especially sample-to-answer systems. (i)
Miniaturized lateral-flow systems have been developed for viral
antigen detection, such as the Binax NOW Flu assay and
Directigen Flu assay from BD for influenza A detection.74
These techniques suffer from a lack of sensitivity (from 53% to
59% compared to 80% for macro-scale methods)75 but are fast,
simple, and automated. As an example of magnetic bead-
based sandwich assays, the Architect by Abbott enables the
high-throughput and automated detection of viral antigens
from serum or plasma with a sensitivity of 99%.76 (ii) For
detection of viral genomes, only few devices integrate all steps,
including viral sample preparation, RT-PCR, target capturing,
and detection on a single device, such as the droplet device
proposed by Pipper et al. for avian influenza H5N1 detection
on throat swab samples,77 or the fully integrated device by Cho
et al.78 utilizing a CD platform for Hepatitis B detection. The
protocol, which involves plasma separation from whole blood,
mixing magnetic beads conjugated with target specific anti-
bodies, washing and DNA extraction, was finished within 12
min. Only one initial manual step of loading 100 mL of whole
blood was required, and real-time PCR results were as good as
those from conventional bench-top protocols. However, the
use of cartridges or devices pre-loaded with chemical reagents
brings forth the issue of denaturation and shelf-life during
transport and storage. For these reasons, a recent trend for
integration of viral diagnostics involves exploiting direct virion
detection on-chip, using for instance SPR imaging,79 mechan-
ical cantilevers,80 or electrical conductance methods.81 These
approaches are faster, cheaper, still sensitive, and specific, but
operate reliably only with pure viral samples. Consequently,
some techniques have also been integrated on chip for plasma
extraction and viral particle concentration.69,70,82,83
The next step towards complete integration of on-chip viral
diagnostics will be a unique system which combines plasma
extraction and virus concentration with direct viral detection.
Among others, the on-chip detection from blood and
determination of viral load for HIV, that infects millions of
people worldwide, would have a wide-reaching impact on
healthcare. As an illustration of these future directions, Wang
et al. developed a disposable, pump-free, size exclusion-based
microfilter for both plasma and HIV virion extraction from 40
mL blood in resource-constrained settings.84 Seven HIV-
infected patient samples were processed with recovery
efficiencies as high as 82.5%. Due to the adjustability of the
pore size in their approach, such microchips could target other
viruses, such as influenza.
2.5. Bacteria, fungi and micro-organisms
Bacteria, fungi and various microorganisms potentially lead to
infections and are detectable in plasma. With the rise of public
and political attention on nosocomial (or hospital-acquired)
infections (an average 8.7% of patients are affected through
the world), the rapid and direct detection of microbial
contamination and microorganisms in the bloodstream has
become a pressing matter over the last 10 years.85 Among the
bacteria detection techniques that have been developed on-
chip, Staphylococcus aureus was used as a model in the
development of a miniaturized diagnostic magnetic resonance
(DMR) system.86 In this article, bacteria were detected directly
in spiked human serum samples. While bacteria and fungi
may be found in plasma or serum, it is often directly enriched
from whole blood especially in microfluidic platforms.87,88
However, more recently, bacterial detection has also made use
of PCR techniques for the molecular detection of bacterial
DNA.89 Several groups have demonstrated the use of micro-
fluidic platforms for detecting Staphylococcus aureus,
Mycoplasma pneumonia, and Mycobacterium tuberculosis via
a PCR amplification.90,91 Candida albicans, a morbid type of
fungus found in the blood and the fourth source of
nosocomial infection in the US, has also been detected within
microfluidic platforms via PCR.92 In the case of PCR
amplification of bacteria, fungi, and microorganisms, the
preliminary extraction of plasma from blood is likely to
increase the sensitivity of the detection technique since it
minimizes the presence of background DNA from other cells.
However one article reports an improved amplification in
blood rather than in serum.92
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2.6. Plasma viscometry
Physical characteristics of the plasma itself can be used for
diagnostic purposes and require plasma extraction from blood.
Plasma Viscosity (PV) is considered a routine laboratory measure-
ment and ranges in healthy adults around 1.40–1.75mPa s.93,94 PV
values between 1.75 and 2 mPa s suggest chronic disorders like
infections, malignancy, vascular diseases, and auto-immune
responses such as rheumatic diseases.93,94 Between 2 and 3mPa s,
the PV indicates a myeloma and is actually used as a diagnostic
tool in more than 90% of myeloma cases. Additionally, PV is used
to detect haematological cancers and cardiovascular diseases in
conjunction with other methods.95
In this section, we have highlighted the presence and
diagnostic value of various analytes in plasma. The design of
the plasma extraction device will ultimately depend on the
analyte of interest with a specific application. The following
section introduces some of the challenges encountered for
these different diagnostic applications.
3. Challenges
Miniaturization and integration of blood plasma extraction
offer many advantages. First of all, it allows the separation of
very low-volume samples, from a few microlitres to several
millilitres in a relatively short time, from a few seconds to
several minutes. The scale reduction and lower dead volumes
limit the amount of sample processed to the amount necessary
and sufficient for the analysis. Hence, these systems are more
portable, i.e. transportable to the patient bedside or in the
physician’s office, and several functions can be integrated in
one device. Automated microfluidic systems should also be
easier to use without the need for special training, dedicated
labs, or cumbersome equipment. Secondly, the miniaturiza-
tion of dimensions gives access to additional physical
phenomena, which may enhance the separability of some
biological components compared to macro-scale physics.
Finally, prices are theoretically lower compared to their lab-
scale counterparts, although this varies greatly depending on
the chosen technology, the throughput, and the level of
integration, as the cost expected for a paper device will be
different from a glass or silicon device. However, designers of
microsystems for blood plasma separation also face several
choices and challenges, which are detailed below.
3.1. Sample volume
Miniaturization should not necessarily imply the drastic
reduction of sample volume; despite having a more sensitive
detection in smaller systems, the volume should remain
statistically representative of the analyte targeted. For such
reason, two types of volumes are usually considered, also
corresponding to two distinct methods of blood collection. (i)
Capillary samples refer to sample volumes in the microliter
range, typically a drop of blood collected from the fingertip
(y10 mL). These volumes are especially relevant when the
target is highly concentrated, i.e. present in statistically high
quantity for such a small volume of blood. Several commercial
systems have demonstrated the use of a blood drop for the
analysis of cardiac biomarker proteins such as the BioSite
chip,96 for glucose dosage such as in the FreeStyle Lite
system,97 or for the identification of blood type.98 In all these
examples, the concentration of analytes is high enough to be
detected in a drop of blood with high sensitivity. In the lab-on-
a-chip community, a lot of the research has been focused on
handling these microvolumes. However, the lack of ‘‘killer
applications’’ has more recently led to a reconsideration of
this focus. (ii) In most other applications, such as the
amplification of rare circulating DNA from plasma, analytes
are present below a meaningful quantity in a blood drop, and/
or detection methods are not sensitive enough. In these cases,
volumes in the range of millilitres are more relevant, and are
collected by venous puncture (1–50 mL), but few commercially
viable solutions have been proposed for these samples.
3.2. Sample preparation time
Studies have shown that the quality of analytes in plasma and
serum decreases after a prolonged contact with blood cells.
Plasma and serum are more stable following rapid separation
after blood collection.99 The issues with extended contact with
blood cells may be multiple, including cell degradation
leading to the release of unwanted genomic DNA, haemoglo-
bin, or protein degradation. For example, in the case of non-
invasive prenatal diagnostics, the total level of cfNA increases
with time after blood collection as cell apoptosis occurs.
Consequently the ratio of fetal CNAs versus maternal CNAs is
adversely affected. Plasma extraction is therefore desirable as
soon as possible after blood collection, and in a reproducible
manner as the variation in preparation and consequent
degradation time is a major cause of variability in analysis
results. Microfluidic devices which enable fast and reprodu-
cible plasma extraction, ideally coupled with analyte stabiliza-
tion in situ, would significantly improve analysis
reproducibility and sensitivity.
3.3. Hematocrit level
Hematocrit, the volume percentage of RBCs in blood, often
directly impacts the performance of the separation device.
Hematocrit levels in humans range from 29% in one-year old
infants or patients presenting specific pathologies up to 68%
in newborn babies, with 38 to 54% for healthy adults.
Depending on the targeted applications, some devices may
have to perform similarly in this large range. Some examples
presented in this review show severe drops in separation
performance with higher hematocrit levels, and require blood
dilution before the actual separation to circumvent this
performance drop.
3.4. Clogging
One of the greatest difficulties faced by the engineer creating a
plasma extraction system is the extremely high proportion of
cells in blood, which makes blood very prone to cause clogging
issues in microchannels.14,100 Added to the relative volume of
cells, the intrinsic property of blood to coagulate and the
platelets to aggregate add to the challenge of blood manipula-
tion. Clogging is typically an issue for applications with long
separation time in continuous systems. Some teams propose
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perfusion cycles to tackle this issue and periodically wash the
filters,101 but this approach remains unusual and difficult to
integrate in a long-term device. The most common solution to
avoid such clogging is to dilute the blood with an appropriate
stabilizing buffer. However, this approach introduces not only
an additional mixing step, but also a change in the
composition of the material. Furthermore, it is performed at
the expense of the target analyte concentration downstream.
3.5. Mechanical stress
Under relatively high pressure in microfluidic structures,
several biological entities are at risk of rupturing, such as
RBCs, or starting an adverse activation, such as platelets. In
vivo, the formation of platelet aggregates is triggered by a
range of parameters; however, in vitro, platelet aggregates are
mainly due to a local zone of shear acceleration. A small
aggregate first forms off the vertical wall on the channel and is
gradually expanded by the accumulation of platelets in a tail
made out of fibrin clots and restructured membrane
tethers.102 Yoshimura et al. noticed that, despite a large
amount of heparin in blood, fibrin clots could form in a
microchannel and hinder the normal flow.103 In parallel,
hemolysis describes the rupture of RBCs under mechanical
stress, caused by excessive pressure or shear stress (.1500
dynes cm22),104 or chemical stress such as osmotic pressure.
The main drawback of hemolysis is the release of hemoglobin
in plasma, which may contaminate or hinder subsequent
reactions such as PCR or protein analysis, while RBC ghosts
(membranes) may disturb the flow patterns and separation
mechanism. Therefore, microsystem design for blood plasma
extraction should, as much as possible, avoid the creation of
local zones of high shear stress. The minimisation of local
high shear zones may be possible before manufacturing, in the
development phase, with the use of Computational Fluid
Dynamics (CFD) software.
3.6. Non-specific absorption
Non-specific absorption of biological material on surfaces
such as silicone, plastics or even silicon and glass, is a
common issue in miniaturisation of blood plasma extraction
due to the important surface-to-volume ratio. The lower the
quantity of analytes, the more important the issue. As assessed
by Wong and Ho,105 common solutions to eliminate the
problem include the preliminary saturation of surfaces with
proteins, for instance with Bovine Serum Albumin (BSA),106 or
with a specific surface treatment to render the surface of the
PDMS channel less hydrophobic and less favorable for
biological materials to anchor. Most common surface treat-
ments include PEG, different types of silanization, or oxygen
plasma treatment.107,108
3.7. Contamination
Contamination from one blood sample to the other is
generally averted by using single-use devices. However, this
attribute must be determined in the design phase as it impacts
the manufacturing technique associated with the device, the
packaging, and instrument used for injection, and ultimately
on its total cost.109
3.8. Biocompatibility
Biocompatibility is an ambiguous concept and a vastly
complex subject. Here, the challenge is to find the right
material adapted to a specific application, which minimises
the risk of non-specific absorption, hemolysis, and platelet
activation. Though essential, this point seems too rarely
emphasized in the literature, and may be a source of failure
in the translation of research to market.109–111
3.9. Product life cycle
The life cycle of microfluidic chips is rarely considered. As
most blood plasma separation devices will not be reusable due
to contamination issues between samples, they are usually
thrown away. This may result in a vast amount of non-
degradable plastics being thrown away each year. Few research
groups have addressed this issue, but some examples of
‘‘green’’ microfluidic chips, made out of poly(lactic acid) (PLA)
or natural-based materials, such as zein, have been demon-
strated in the literature as early as 2004, though none of them
have been demonstrated in the field of blood plasma
separation.112–114 These studies have shown the possibility to
manufacture microfluidic structures out of biodegradable
polymers. However, and regrettably, the shelf life of the
devices was not investigated. Shelf-life of biodegradable
polymer chips might be significantly lower than conventional
plastic ones, and should be considered during technology
commercialisation efforts.
3.10. Characterisation techniques
Optimum on-chip blood plasma separation techniques should
have a large throughput, a high plasma yield and purity, and
minimum cellular damage in order to prevent contamination
of the plasma with cellular DNA and haemoglobin. Although
not a direct engineering challenge, characterisation techni-
ques should be taken into account during the testing phase of
blood plasma separation microdevices. Performance in terms
of separation efficiency and purity have been assessed in the
literature using different devices, including hemocytometers,
automated cytometers, and flow cytometers, which all provide
different metrics and precisions. These differences have to be
considered with caution as they make comparisons of existing
approaches and performances quite challenging.
Furthermore, blood plasma separation devices may be further
validated using common biological techniques as previously
described by the authors,115 such as (i) spectrophotometry for
red cell lysis and evaluation of hemoglobin release (Cripps
Method116), (ii) absorbance measurements at 280 nm to
estimate the total amount of proteins and potential protein
loss through the device, (iii) capillary electrophoresis, such as
Bioanalyser Agilent, to confirm the presence of major proteins,
(iv) enzymatic assays for evaluation of protein denaturation or
(v) by performing PCR on DNA present in the plasma
extracted.117 Such biological characterisation is important to
demonstrate the utility of the device in a real-life clinical
setting and should be considered cautiously depending on the
application targeted.
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4. Formats and solutions for miniaturised
blood plasma extraction
Various solutions are available for plasma extraction at the
macro-scale depending on the desired sampling volume: blood
transfusion volume (500 mL), analytic venous sample (1–50
mL), or blood droplet from a finger-prick (y10 mL). Plasma
extraction from a large volume of blood for transfusion
purposes (a procedure named plasmapheresis) specifically
requires continuous separation, with high-throughput and
efficiency over time. Such separation is performed using
centrifugation and rotation chambers, coupled with single-use
plastic consumables. Transfusion equipment is large (over 1
m3), heavy (over 10 kg), expensive, and necessitates complex
fluid handling, but efficiently extracts and cleans plasma
before re-injection in the donor or in the patient. A review of
the macro-scale techniques existing for plasmapheresis has
been presented by Stegmayr.118 Filtering membranes are also
commercially available and commonly used in clinical settings
for dialysis, transfusion or therapeutic plasmapheresis. For
venous sampling and most blood analyses performed in tubes,
the conventional procedure used to separate plasma from
blood cells includes centrifugation (5 min at 1500g), followed
by physical separation with a pipette. This technique is simple,
commonly and daily performed by clinicians, researchers, and
technicians all over the world, but is still manually intensive at
a macro scale, with a multi-step process that is prone to
human error. Analytical centrifugation can be high throughput
and fully automated, but necessitates relatively expensive
equipment. Filtration may also be used for such volumes,
usually directly at the point of extraction, i.e. with a filter
adjustable on a syringe. Therefore, whatever the blood volume
processed, the two conventional mechanisms—centrifugation
or filtration—exploited for plasma separation at the macro-
scale remain ubiquitous.
Fig. 3 Technological solutions for micro-scale plasma separation. (A) Three different formats are currently used for micro-scale blood plasma separation. (B) A wide
range of solutions have been developed for blood plasma separation in microfluidic chip format. Two categories make up the top-level classification of blood plasma
separation techniques in microfluidic chip formats; techniques without external field (i.e. where separation occurs with hydrodynamic forces and built-in geometrical
features) and techniques where an external field is used to force the separation of plasma from blood cells (Acoustic, Electric or Magnetic field).
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On the contrary, a variety of solutions are available for
miniaturised blood plasma extraction, which has currently
been performed in three main formats (Fig. 3): (i) the
microfluidic chip format, featuring fluid flowing through
microchannels and based on classical microfabrication
techniques, (ii) the CD format, based on a radial geometry
and exploiting the laser CD developments, and (iii) the paper
format, based on capillary flow migration on a cheap and
biodegradable resource. Within the microfluidic chip format,
separation techniques are generally classified in two distinct
categories; the passive methods, based on flow properties in
the microscale, as opposed to the active methods, that require
an additional external field. Active and passive microfluidic
chip approaches are assessed in Parts 1 and 2 of this section,
while the CD and paper alternatives are detailed in Parts 3 and
4 respectively.
4.1. Microfluidic chip format and passive separation
Passive separation techniques, i.e. separation techniques
without external fields, refer to those methods utilising only
physical forces within the flow to induce plasma extraction
from cell components. It is opposed to the sorting methods
which apply an external force field, such as acoustic, electrical
or magnetic field. To tackle the potential problems of such
outer force field requirements in microdevices, researchers
proposed some techniques typically coined as ‘‘passive’’ or
‘‘fluidic-only’’. In these separation methods, particles are
sorted exclusively by their mechanical properties, such as size,
shape, and deformability, using only the geometries of
microchannels or microstructures within the microchannels,
the flow itself, and inherent hydrodynamic forces. Passive
techniques were also the bases behind the first attempts of
separation miniaturization, as researchers logically tried to
first reproduce in smaller scales some principles that were well
known and validated in the macroscale.119
4.1.1. Sedimentation. Sedimentation is the oldest diagnostic
technique used in haematology. Sedimentation velocity of red
blood cells ranges from 0.27 to 3.8 mm s21, depending on the
sex and health status of the patient, and is representative of
patient pathologic states and inflammations.120 The principle
is simply based on differential cell sedimentation within tubes
or channels due to the gravity and differences of blood
component densities (rred cells = 1100, rwhite cells = 1050–1090
and rplasma = 1030 kg m
23). Sedimentation has been translated
to micro-scale systems for plasma extraction applica-
tions.121,122 For instance, using microfluidic sedimentation
and plasma collection in upper branch channels with low
depth, Yoon et al.121 extracted 20% plasma from non-diluted
blood at 0.1 mL min21, with 6 to 30 mL processed in 1 h
(Fig. 4A).
Sedimentation advantageously reduces clogging issues
inherent to microfiltration, as RBCs sediment away from the
entrance of filter parts, enabling the free flow of plasma
through the filter. As an illustration, Tachi et al. combined
sedimentation and cross filtration featuring two parallel main
channels connected via 1 mm deep shallow trenches.122 1 : 6
diluted blood samples are injected at 1 mL min21 into the
blood inlet, while a buffer is injected in the second channel at
the same rate. RBCs gradually sink down the 20 mm long
channel while plasma flows freely within the second channel.
Although few platelets passed in the plasma collection
Fig. 4 Plasma extraction using sedimentation. (A) Sedimentation and filtration, with 20% plasma collected in upper branch channels. Adapted from ref. 128. (B)
Sedimentation is advantageously exploited with a back-facing-step, for 4 h of continuous blood perfusion at 15 mL min21. Adapted with permission from ref. 129.
Copyright 2012 American Chemical Society. (C) Sedimentation in a blood droplet blocked by oil plugs, with plasma extraction combined with cholesterol colorimetric
assay. Adapted with permission from ref. 56. (D) Sedimentation of red cells in trenches for capillary extraction of plasma, combined with ELISA assay to measure biotin
levels. Adapted with permission from ref. 127.
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channel, no blood cells were detected. Moreover, the haemo-
globin concentration was measured to be less than 1 mg dL21,
which is not likely to influence further molecular analysis.
A sedimentation approach with a backward facing step for
continuous plasma separation was described by Zhang et al.123
The key strategy in this design is to keep the natural
sedimentation of blood cells unperturbed in a glass capillary
channel, while the separation of plasma from the cell phase is
facilitated by the addition of a constriction and a back-facing
step (Fig. 4B). The purity reached 99% at 15 mL min21, but
decreased at higher flow rates and for 8% Hct (y1 : 5
dilution). No clogging was observed during 4 h of continuous
perfusion.
A capillary-driven system taking advantage of RBC sedimen-
tation rate has been recently demonstrated by Wu et al.124 The
system comprised two deep-seated reservoirs connected by a
series of parallel channels sitting above the reservoirs and
featuring filter pores and chambers, respectively 6–10 mm and
50–100 mm high. On one end, the reservoir is filled with blood,
where RBCs start sinking toward the bottom. The top part of
the reservoir is sucked by capillarity into the parallel channels,
where the passage of the remaining RBCs is hampered by the
combination of pores and chambers. After a number of pores,
no RBCs remain in the plasma channel (by visual observation)
while the plasma keeps flowing towards the outlet reservoir.
However these results are demonstrated with a diluted blood
sample (Hct between 0.2% and 20%), since clogging issues
leading to the device failure were reported for whole blood and
1 : 2 blood dilution.
Recently, Sun et al. also proposed a novel sedimentation
strategy coupled with a droplet generation system.56 In this
new approach, a finger-prick blood droplet is sucked by
capillarity into an oil-filled piece of tubing and blocked by a
second plug of oil. Blood samples need to be at least 1 : 5
diluted before separation can occur, within 120–240 s at 0.5 mL
min21, with higher flow rates leading to a weaker separation
effect (Fig. 4C). While sedimentation was demonstrated as the
principal effect responsible for blood cell separation, the
kinematics of the plug may also play a role. This plug-based
plasma separation offers an opportunity to incorporate low
shear rate (1 s21) blood plasma separation with droplet-based
technologies. A colorimetric assay for the detection of
cholesterol was elegantly integrated within the same device
and demonstrated the biological validity of the plasma
extracted.
Sedimentation is sometimes used in combination with weirs
or trenches to optimise and speed up the plasma extraction
process.125–127 Dimov et al. used a trench in a capillary-driven
system to extract plasma from a 5 mL droplet of blood, and
integrated an ELISA assay in their Stand-alone Integrated
Microfluidic Blood Analysis System (SIMBAS) to detect biotin
levels.127 While blood cells fall and are trapped in a 2 mm deep
trench, the plasma is extracted by capillary force into upper
channels, further coated with antibodies for the ELISA assay in
situ (Fig. 4D). In this study, 100% separation purity was
obtained through image analysis for flow rates lower than 50
mL h21, even with artificially high hematocrit levels (74%).
Biotin was detected on spiked blood samples in concentra-
tions as low as 1.5 pM.
In all these examples, the separation throughput is
necessarily low, as any increase in flow rate will result in the
instability of the separation interface. In consequence, the
sedimentation approach is not adapted for rapid separation of
large volumes of blood, a major limitation to this technique.
However, sedimentation has several specific advantages,
which still makes it a powerful solution compatible with
small volumes (finger-prick volume) and capillary pumping,
and explains the recent publication of new devices.
Sedimentation can easily be used without the need for blood
dilution and offers a very effective solution in terms of
separation efficiency. Also, coupling with filtering geometries
can be further optimized to increase extraction yield.
4.1.2. Microfiltration.Microfiltration is another example of a
macroscale conventional blood separation method that has
been miniaturized. As in its macroscale counterpart, micro-
filtration is simply based on particle size differences and
selective segregation by well-dimensioned pores. Several
microfilter designs exist, varying in terms of their critical pore
size, blood passing capability, and trapping or filtering
efficiency.
Dead-end microfiltration. Membranes, pores, and packed
beads have been created to allow the flow-through (or dead-
end) filtration of plasma from blood for miniaturised
applications.
The membrane often corresponds to the integration of a
macroscale and commercial filtering membrane within a
microsystem for a 2D-filtration.130 Thorslund et al. integrated
a polymeric membrane with pore size of 0.40 mm between two
PDMS slabs. To avoid hemolysis and RBC leakage, the blood
samples had to be diluted down to 20% Hct with a sealed
polypropylene (PP) device. Testosterone absorption tests
showed that some protein fouling happening on the PDMS
surface did not preclude its detection (91% recovery). In ref.
84, a filter membrane (with 2 mm pore size) cut from
chromatographic paper is sandwiched in a reservoir between
several layers made out of several laminated PMMA laser-cut
layers. 40 mL of blood were injected, followed by a minimum of
200 mL of PBS buffer, at flow rates ranging from 100 to 500 mL
min21, forcing the cells against the filter and washing plasma
through the collection chamber. Plasma purity reached 97.9%
with pore sizes of 0.4 mm, but the collected volume was only 55
mL since the filter clogged very quickly. The collected volume
reached 220 mL with pore sizes of 3 mm, but the purity dropped
to 74.9%. The plasma quality was successfully assessed by
using HIV recovery test, which showed up to 89.9% recovery
for a viral load of 1000 copies per mL. Moorthy et al. presented
a device with an integrated membrane, or porous plug,
allowing the filtration of cells larger than 3 mm.131 The porous
plug is a pre-polymer mixture containing a cross-linker for
hardening the plug after photopolymerisation. After the pre-
polymer mixture is drawn into a channel by capillary action
and cured, incubation in water prior to the separation allows
the plug to swell from its dried shrunken state. Rabbit blood
was diluted 1 : 20 and incubated in hypotonic solution to
make the cells swollen and less flexible, thus less likely to pass
through the porous pores. After a certain volume, the filter is
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clogged by cells, and the cross-sectional area of the filter
governs the total plasma yield. Here 20 mL of plasma could be
extracted for an unknown volume of blood, at flow rates up to
10–20 mL min21. The concentration of G-6-PDH enzymes in the
plasma extracted on-chip was found to be equivalent to plasma
extracted by centrifugation.
Silicon-based filter materials were used by Lee et al. to
manufacture a planar filter with well-defined pore geome-
try.132 These filters, made out of a Si3N4 layer and a SiO2 stress-
release layer, allowed for the separation of 1 mL plasma out of 5
mL blood. Although the authors reported visual observation of
hemolysis at the filter outlet, an SDS-PAGE analysis did not
reveal significant amount of haemoglobin (data not commu-
nicated). A small agarose gel block was attached to the back of
the filter and reported to enhance the plasma flow through the
filter via an increase of the capillary suction due to the porosity
of the gel. Microscopic images of the gel do not show RBCs
passing through the filter. The gel was melted down and
analysed for the presence of plasma proteins, such as albumin.
Clogging of the filter occurred after 5 min of use, and although
the filter seems effective, it is not clear why such complexity
would be necessary, unless the silicon filter was integrated to a
silicon chip for a specific purpose such as refining the sensing
of plasma analytes.
Bead-packed microchannels may be an easier way to
incorporate effective blood plasma separation functions into
capillary-driven blood analysis systems.133–136 In ref. 133, 10 to
20 mm silica beads were packed against a bump in the main
channel of a Cyclic-Olefin Copolymer (COC) device. Protein-
blocking solution was coated on the channel and bead walls in
order to change the hydrophobicity of the channel surfaces.
Some improvements include the use of two different bead
sizes, with 100 mm-sized beads to block the inlet channel
entrance and 10 mm ones to act as a filter, which leads to the
separation of 350 nL of plasma from 5 mL of undiluted blood
in less than 2 min.134 In another example, the plug was created
by the evaporation of water in a bead slurry (beads ranging
from 0.9 to 10 mm) injected at the entrance of the separation
channel in a PDMS slab.135 10 mL of a whole sheep blood
droplet was drawn by capillary action through the separation
channel and bead slurry (Fig. 5A). 188 nL of plasma was
extracted from 10 mL of whole blood in 10 min. In another
article, plasma extracted on the same system from whole blood
was validated through the detection of immunoglobulin (IgG),
the main antibody responsible for fighting infection in body
tissues.136 The detection occurred on antibody strips immo-
bilised on the PDMS slab in the reaction zone located
downstream from the deposited microbead-plug (DMBP).
Here, the DMBP has a double function by also serving as a
carrier for the labelled conjugates, which combines elegant
plasma extraction with target analysis.
While most examples require some pumping techniques or
are self-actuated via capillary pumping, Chung et al. proposed
an interesting magnetic actuation, where 3 to 8 filter
membranes were sandwiched between a permanent magnet
and a chip with a single channel in a plastic casing (Fig. 5B).137
Fig. 5 Examples of blood plasma separation using microscale filtration. (A) Dead-end filtration with packed beads (DMBP) and capillary-flow actuation.135 Red blood
cells remain trapped within the bead plug while plasma can flow through the beads. The DMBP can be further used as a carrier for labelled conjugates, for bioassay on
the plasma extracted. Adapted with kind permission from Springer Science and Business Media from ref. 136. (B) Dead-end filtration with membranes and magnetic
actuation. A non-diluted blood sample is dropped into the filter unit. Magnetic attraction is applied to squeeze out only plasma while blood cells are filtered by the 6
membranes stacked together in the filter unit. Adapted from ref. 137. (C) Example of cross-flowmembrane filtration. Left. The bottom compartment is a filtrate channel,
where plasma flows across a semipermeable membrane from the top reservoir into the filtrate channels. The activated membrane and these 2 PDMS layers are bonded
together to form a sandwich structure. Adapted from ref. 46. Right. This device is shownduring blood perfusion for cardiopulmonary bypass procedures. Original photograph
kindly provided by J. D. Zahn and K. Aran.
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After a few drops of blood have been pipetted on the
membranes, (i) an external control magnet is brought under-
neath the chip, which (ii) attracts the permanent magnet
located on the filter membranes, and (iii) squeezes the
membranes to (iv) enable the extraction of 7 mL of plasma
from 50 mL of whole undiluted blood in less than 1 min. The
purity obtained was close to 100% (via hemacytometer
counting). Although the system could be further optimized,
it might be a practical actuation mechanism to replace or
complement capillary actuation in some cases.
Cross-flow filtration. In cross-flow filtration, the fluid flows
tangentially rather than through the filter as it does in
membrane filtration. This type of filtration is widely used in
several industrial applications, including those in chemical
engineering and bioengineering, and has been rationally
applied in microsystems for blood plasma separation and
on-chip extraction purposes.
Crowley et al. proposed several planar microfilters138 based
on cross-flow filtration and capillary actuation. The plasma
can flow freely through pores (200 mm wide, 0.5 mm high, and
50 mm long) arranged longitudinally across the channel length.
14 to 45 nL of plasma were extracted from 5 mL of whole (40%
Hct) or diluted (19% Hct) bovine blood, with an output plasma
flow rate ranging between 35 and 175 mm s21. The plasma was
observed by microscopy and showed no trace of cell or cell
debris. No further characterisation was performed on the
extracted plasma. In ref. 100, a cross-flow design was proposed
with a network of channels to counteract the effect of PDMS
compliance, which can lead to channel deformation and thus
create uneven device performance. Furthermore, the authors
also used h-PDMS, which has a Young’s modulus four times
higher than PDMS. Interestingly, a back-pulsing strategy
minimised the filter structure clogging and 10% of plasma
was extracted from 20% Hct blood samples at 1 mL min21,
while hemolysis was measured via the Cripps method at
0.08%. Chen et al. developed cross-flow filtration devices using
an array of posts as well as weir structures, and indicated the
capability of retrieving plasma containing ‘‘only a few blood
cells’’, with no further characterisation.139 Sollier et al.
proposed original cross-flow filtering geometries, featuring
U-shapes and serpentine designs,140 but performing only 5%
extraction from 1.4 mm deep filters and 1 : 10 diluted blood. In
another cross-flow solution proposed by Aran et al. and
dedicated to the continuous monitoring of inflammatory
response during cardiopulmonary bypass procedures (cf.
section 2.2), the device consists of two slabs of PDMS
separated by a porous polycarbonate (PCTE) membrane with
100 to 200 nm pore sizes as pictured in Fig. 5C. While the 200
nm pore size initially provides a higher output flow rate, it also
clogs faster.46 Heparin was used on the blood samples in order
to avoid protein fouling on the membranes and reduce
clogging. 15% of plasma was extracted from heparin-treated
and slightly diluted blood (27–30% Hct) with high purity
(100%, the characterisation technique not being specified) at
80 mL min21. The device was connected to a cardiopulmonary
bypass (CPB) circuit, and plasma was collected over a 4 h
period with 80% of plasma proteins recovered.
As shown in these examples, dead-end and cross-flow
filtrations are efficient but most of the time relatively short-
term solutions for separating plasma from cell suspensions. A
low flow rate is preferable, but it increases the risk of protein
adhesion in the filters. The major drawback of such
techniques is the risk of clogging, which limits their
performance by the saturation time of the filter. The entrance
to the filter pores is quickly clogged and eventually red blood
cells might pass through the filter pores due to their
deformability. Thus, these techniques are efficient but only
for a certain time defined by saturation, for a given volume
and a diluted sample, at low flow rates. Optimized filtration
might call for more complex fabrication technologies, espe-
cially when small filter pores are required,132 but can also
make use of simple chromatographic paper integrated in
microfluidic channels.84,137 Most importantly, these examples
differ fundamentally from the paper format devices described
in Section 4.3, where whole assays are performed on paper,
which acts as the filter as well as the support.
4.1.3. Cell deviation. The natural or forced deviation of cells
flowing in microchannels has been exploited to effectively
extract plasma from whole blood. Cell deviation techniques
assessed here include deterministic deviation by obstacles,
deviation by viscous or inertial lift forces in straight channels,
as well as in curved channels with the additional presence of
centrifugal forces and Dean vortices.
Deterministic deviation by obstacles. As emphasized with
microfiltration approaches, microstructures can be arranged
with intervals well adapted to the dimensions of the cells
being filtered. Microstructure arrays can be also exploited to
alter cell streamlines, as in Deterministic Lateral Displacement
(DLD). The first DLD system was set up and tested by Huang
et al.141 with micro-pillars of circular cross-section and
arranged in rows within a microchannel. Each row of pillars
is shifted from the other by a distance which partly sets the
critical size cut-off. The asymmetric bifurcation of laminar
flow around these obstacles leads particles to choose their
paths deterministically on the basis of their size. A small
particle will have a zig-zag displacement path, whereas a large
particle will tend to flow straight. After several rows, the
particles can be collected separately. In ref. 142, this method
was successfully applied to blood samples, with one device
(FD) demonstrating the fractionation of WBCs and RBCs and a
second one (PD) showing plasma extraction. In the PD device,
plasma was separated from RBCs, WBCs and PLTs in a cascade
device with anti-clogging features, at an injection rate of 0.4 mL
min21. The flow of plasma was visually observed with the
unbound PLT antibodies forming a uniform bright back-
ground in the device. However no biological validation was
performed on the extracted plasma. An optimized version of
the same device was later focused on the measurement of
platelet size and morphology in platelet-rich-plasma (PRP) and
included upstream a DLD array for the removal of RBCs and
WBCs from whole blood.143 However, plasma itself was not
characterised in this second study either.
In another example by Choi et al., a micro-pillar array is
replaced by slanted obstacles for the efficient extraction of
This journal is  The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 3323–3346 | 3335
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plasma.144,145 The combination of hydrophoretic separation
with a vertical weir placed in the pathway of the lined up
particles enabled size fractionation. The larger particles do not
pass through the narrow gap but instead follow the obstacle to
a larger gap at the other side of the channel. The yield of
plasma in this device was close to 40% for 1 : 4 diluted rat
blood at a flow rate of 4 mL min21 (Fig. 6A).145
Laminar and deterministic deviation by microstructures is a
powerful and robust separation mechanism, which also
suffers from various drawbacks, including the necessity of
extremely low flow rate, significant dilution of the sample,
along with the precise and consequently expensive fabrication
process. Last but not least, especially obvious for the DLD
technique, the number of pillars employed and the narrow
gaps between them bring a high risk of clogging, which
explains why DLD has rarely been adapted exclusively for the
separation of plasma.
Hydrodynamic separation, starting from viscous lift forces.
Hydrodynamic separation techniques are particularly relevant
in the case of blood plasma separation, where the natural axial
migration of blood cells in microchannels, sometimes referred
to as the Fahraeus effect, or plasma skimming, can be
exploited as the sorting mechanism. Briefly, the Reynolds
number, a dimensionless number, gives a ratio of inertial
forces to viscous forces.146 For Reynolds numbers lower than
1, viscous forces are expected to overcome inertial forces,
yielding flows in microchannels that are expected to be
laminar and devoid of turbulence. Such flow characteristics
also occur in blood capillaries where, due to lift forces applied
to cells in microchannels, deformable red cells undergo a
lateral migration.147 Thus, a boundary-layer a few microns
thick, named the cell-free layer, becomes depleted of red cells,
making it possible to extract a clear plasma volume by
branching off this cell-free layer into an appropriate side
channel. Microcirculation effects also include the Zweifach–
Fung bifurcation law. Fung et al. demonstrated that cells at a
bifurcation have a tendency to travel to the highest flow rate
daughter channel, provided that the flow rate ratio is at least
2.5 : 1 and the dimensions of the cells are comparable to the
channel diameter.148 This effect has often been described by
the asymmetrical distribution of pressure and shear forces
Fig. 6 Examples of blood plasma separation using hydrodynamics and cell deviationmechanisms. (A) Separationwith slanted obstacles. The generation of transverse flow due
to the presence of slanted obstacles allows the concentration of red blood cells towards the center of the channel. Diluted rat blood was injected for demonstration in they7
mm high channel Adapted from ref. 145. (B) Separation using a viscous lift force. Top: An illustration of the Zweifach–Fung effect at a bifurcation. As explained in ref. 149, the
effect does not result, as previously thought, from an attraction towards the channel with the highest flow rate, but rather from the initial distribution of cells in the channel.
Bottom: The use of several plasma channels placed in parallel and along themain channel allows the extraction of plasma. Adapted from ref. 154. (C) Top: Separation based on
biomimetic effect, such as the Zweifach–Fung effect, but at a higher flow rate (up to 0.33 mL min21). The scale bar is approximately 50 mm. Adapted from ref. 152. Bottom:
Similarly, other devices can expand the initial cell-free layer to increase plasma extraction yield. Adapted from ref. 115. These designs are based on red blood cell lateralmigration
and the resulting cell-free layer locally expanded by geometric singularities such as the effect of a restriction, an enlargement of the channel or a cavity adjacent to the
channel. (D) Separation using inertial lift forces. Top. Inertial lifts acting on large blood cells lead to their migration to equilibrium positions, located near the channel
walls. RBCs can then be collected in side channels, while the plasma rich in bacteria is extracted in the middle outlet. This geometry can be advantageously parallelized,
with 40 channels placed in a radial array, 1 inlet for injecting blood at 8 mL min21, and 2 rings of outlets respectively for filtered blood and blood plasma collection.
Adapted from ref. 106. Copyright E 2010 Wiley Periodicals, Inc.
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applied on the cell at the bifurcation, which might ‘‘pull’’ the
cell to the channel with the highest flow. However, it was
recently demonstrated that the basis of this effect is probably
due to the initial repartition of particles in the channel, as the
cell-free boundary layer itself is enough to allow the extraction
of plasma though lateral bifurcations.149
These physical laws derived from microcirculation have
been studied, used, and mimicked to design microstructures
for continuous plasma separation.115,150–152 Faivre et al. first
mentioned the use of this natural cell-free layer for plasma
extraction on-chip, further demonstrating that a restriction or
constriction of the microchannel increases this cell-free layer
up to 1 cm downstream for specific geometries.150 During the
continuous injection of 16% Hct blood at 200 mL h21, 24% of
the plasma originating from this expanded cell-free layer was
extracted with two lateral collection channels. However, the
blood was initially modified with washing steps, and no
further estimation of the extraction purity nor biological
validation were provided. By using a pure viscous lift force,153
Geislinger et al. separated platelets from RBCs from highly
diluted samples (Hct = 0.1%) at low flow rates, ranging
between 20 mL h21 to 750 mL h21. Citing the Zweifach–Fung
law, Jaggi et al. presented a three-dimensional structure that
took advantage of a high-aspect ratio to produce a better
plasma yield.151 Yang et al. also used the Zweifach-Fung law in
their design,154,155 where 100% pure plasma (purity checked
through image analysis) from sheep blood was extracted with
up to 25% yield and an extraction rate of 4 mL min21 (Fig. 6B).
A bar-coded protein detection system integrated in the plasma
channels was coupled with this technique,156 and although the
system was not tested with whole blood, the detection of hCG
and a dozen protein cancer biomarkers was demonstrated on
clinical serum.
Although all these examples draw their inspiration from
long-standing microcirculation laws with low Re, the flow rates
used in most of these extraction devices are relatively high.
Inertial forces probably occur and combine with viscous
forces, leading to an even stronger lift on the blood cells,
which increases the efficiency and throughput of blood
separation devices, as this is certainly the case in ref. 115,
117, 152 and 157. For instance, Kersaudy-Kerhoas et al.
presented a system with a network of bifurcations allowing
the separation of plasma from blood with up to 60% purity
and 40% yield for diluted blood at relatively high flow rates (2–
20 mL h21) (Fig. 6C).117 Later on, after adding a constriction
which enhances the cell-free plasma layer before each
bifurcation, the purity was raised to 100% for whole blood at
high flow rate (10 mL h21), but at lower plasma yield
(y8%).152 The purity of the extracted plasma was successfully
validated by the direct PCR amplification of a house-keeping
gene (GAPDH) from CNAs. Furthermore, the CNA detection
was validated for various dilution ratios and purity levels.
Other original geometries have been proposed to locally
amplify the initial cell-free layer. For instance, Sollier et al.
showed that the clear plasma region could be expanded locally
by certain geometric singularities, such as an abrupt enlarge-
ment of the channel or a cavity along the channel (Fig. 6C).115
These singularities create vortex flow patterns, which help by
cleaning the plasma from contaminating red cells and
increasing the extraction yield, providing a 3-fold improve-
ment over the reference device simply extracting the initial
cell-free layer. The extraction yield was around 18% for 1 : 20
diluted blood injected at 100 mL min21. Additionally, extracted
plasma was biologically validated, with no protein loss or
denaturation, no hemolysis, and with excellent cell purity for
red cells, platelets and white cells. Temperature was found to
increase the cell-free layer by up to 250% in another device
using relatively high flow rates (up to 12 mL h21) to extract
plasma through constrictions and bifurcations.157 A purity of
97% was obtained with an entrance flow rate of 200 mL min21
and a temperature of 37 uC. A plasma yield of 3.5% was
reported but no biological validation of the plasma was
proposed.
These devices, mimicking blood microvascular networks,
are especially attractive for continuous plasma extraction.
Based on a purely passive fluidic principle, with no need for
filters or external force fields, these devices are compatible
with high flow rates. The designs are simple, with no
restricting dimensions and do not require any complex
fabrication technology. For all these reasons, such designs
make it possible to integrate rapid plasma extraction in a lab-
on-a-chip or could even serve as a stand-alone application. A
new range of separation techniques has also recently arisen
from the use of pure inertial hydrodynamic effects.
Moving on to inertial hydrodynamic separation within straight
channels. Against widespread thinking that inertial forces have
no action in microfluidic systems, Di Carlo and others have to
be acknowledged for demystifying the area158 and demonstrat-
ing that inertial focusing can actually separate and concentrate
microparticles and cells in microchannels63,158,159 at Reynolds
numbers higher than 1. Briefly, inertial particle focusing is
based on the superposition of two inertial lift forces, (i) a shear
gradient lift force, due to the shear rate of a parabolic flow,
that is directed towards the channel walls, and (ii) a wall effect
lift force, due to reflection of a particle’s wake, that is directed
away from channels walls. Consequently, diluted suspensions
of particles flowing in confined channels with finite inertia
will migrate across streamlines to occupy dynamic equilibrium
positions located approximately halfway between the channel
centerline and walls. This phenomenon has been first
emphasized by Segre´ and Silberberg in cylindrical channels,
where particles focus to an annulus within the channel cross-
section.160 In square or rectangular channels, inertial lift
forces also focus particles, reducing these positions from an
annulus to four precise locations, at a rate that depends on the
particle and channel diameter. By changing the symmetry of
the channel (i.e. for a very wide or very tall channel), single-
point focusing can be achieved and has been successfully
applied to blood cells for high-throughput cytometry.159
Subsequently, by splitting the outlet channel in correspon-
dence to the streamlines, focused particles can be collected in
a smaller volume and significantly concentrated.161
A device using such technology was introduced by Di Carlo
et al. to remove plasma and pathogenic bacteria during
transfusion (Fig. 6D).106 Each single channel consists of a
focusing length followed by a gradual expansion and collec-
tion region. Blood cells align themselves near the walls, where
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they can be collected in side channels, while plasma is
extracted in the middle outlet with bacteria. Separation
experiments were conducted with whole human blood diluted
to 0.5% v/v in PBS, spiked with E. coli and injected at 200 mL
min21. More than 80% of plasma and pathogenic bacteria
were extracted from blood after two passes, with 82% of the
RBCs being collected in cell outlets (i.e. 18% of the RBCs
remaining in the plasma), and 5% hemolysis. The main
interest of this work was the massive parallelization of the
separation unit, which enables the continuous processing of
large volumes of sample (30 mL) with extreme throughput (8
mL min21 as total flow rate, with 400 million cells min21). 40
single devices were placed in parallel, with one single inlet and
80 outlets, for a final footprint of 7 by 7 cm. In this design, the
side outlets formed an inner ring for blood cell collection,
while an outer ring of outlets was used for collecting blood
plasma. Lee et al. proposed a series of expansions and
contractions to vary channel aspect ratio and modify the
amplitude of inertial lift forces.162 This device was applied to
the continuous plasma extraction from whole blood, at
relatively high-throughput (1.2 mL h21 and 1 6 108 cells
min21) and high efficiency, with 62.2% extraction of the
plasma in lower outlet. However, plasma collected off-chip was
significantly diluted by PBS via co-flow (12 mL h21) and the
plasma purity was poor, with a RBC rejection ratio of only 60%
(i.e. collected plasma still contains 40% of the RBCs) which
was also visually confirmed by the outlet photographs
included in the paper. Multiple serial processing steps would
be interesting with such a device to improve plasma purity
while maintaining high-throughput. More recently, Amini
et al. have introduced an innovative strategy to program fluid
motion using the inertial flow deformations induced by
sequences of microstructures combined with inertial focusing
for accurately controlling the motion of particles/cells.163
Using a specific program, the cross-stream translation of the
fluid surrounding particles has been demonstrated with 72%
of the liquid being extracted in one outlet, with only 1.4% of
particle contamination. Such deterministic control of both
particles and fluid motion represents a promising approach
for continuous and fast plasma extraction from blood.
Hydrodynamic separation in curved channels. By using
channels with curvature, an additional drag force arising from
secondary flows – Dean vortices – balances these inertial lift
forces and has been shown to enhance the speed of particle
migration to more stable equilibrium positions.164
Consequently, the focusing of particles is faster than in
straight channels. The use of curved channels originally came
from attempts to master centrifugation in microsystems, not
by using the centrifugal force induced by a rotating element
but instead the one induced by flow in curved channels.14
Dean vortices, well described in the literature,165,166 consist of
a pair of counter-rotating helical vortices located symmetri-
cally with respect to the mid-plane of symmetry of the channel
curve. Cells or particles flowing through a curved channel are
then exposed to two lateral forces in addition with inertial lift
forces. The centrifugal force makes the particles with higher
density travel towards the outer channel wall, whereas Dean
vortices tend to mix and disperse the beads due to the Dean
drag force. Di Carlo and others have demonstrated the precise
control of these forces for accurate particle focusing and its
application to high-throughput and continuous blood separa-
tion.166–168 However, such a mechanism requires significant
blood dilution, such as the 2% dilution considered in ref. 167.
An original 180u bend device was also proposed in ref. 14,
coupling inertial migration in a straight channel with Dean
forces in the curve. The device was tested with 1 : 20 diluted
blood and plasma separation was visually observed, but no
quantitative data was provided. Blattert et al. proposed a bend
structure to increase the plasma free layer existing naturally in
microchannels by imparting a centrifugal effect to force them
on one side of the channel.169 Li et al. reported the extraction
of 124 mL of plasma (purity not communicated) from 250 mL of
slightly diluted blood at a flow rate of 10 mL min21 in a spiral
device combining cross-flow filtration, Dean vortices and
centrifugal effects.170,171 More recently, Morikawa et al. intro-
duced a spiral microchannel for blood injection at 5 mL
min21, separation of plasma at 90% (no indication of the
protocol used), and use of the plasma/serum extracted for dry
eye therapy.172
While viscous lift forces and biomimetic effects may be
effective, these techniques are severely limited by slow flow
rates. On the contrary, inertial effects at the microscale appear
extremely promising in enhancing the natural cell-free layer
and addressing the plasma extraction challenge, potentially
enabling an approach which is (i) simple and requires no
complex fabrication, (ii) low-cost so that it can be widely
deployed, with (iii) high filtration efficiency resulting in good
purity performance, (iv) high throughput, and finally, (v) able
to operate on large volumes of sample. For all these reasons,
inertial focusing could critically address the current plasma
separation challenges from relatively large sample volumes
(0.5 mL and above), but may be less useful for blood screening
from small finger-prick volumes (y10 mL).
4.2. Microfluidic chip format and active separation
4.2.1. Acoustic separation. Free Flow Acoustophoresis (FFA)
can be considered as one of the most efficient approaches for
high-throughput separation of microparticles or cells from
complex suspensions such as blood samples.31,173,174 A
dedicated review series has been written on the subject.175–177
FFA uses acoustic forces generated by high-frequency acoustic
resonators to separate particles or cells based on their size,
density and compressibility.177,178 As a suspension passes along
a flow path and through a standing wave field, particles will
experience a radiation acoustic force, which translates them
towards pressure nodes or anti-nodes. This force depends on
density and compressibility of the buffer and particles respec-
tively, but also particle volume, acoustic wavelength, pressure,
and distance between particle and pressure node.177
Consequently, a particle gradient canbe progressively developed
across the channel. Due to laminar conditions, the focused
particles will remain in their lateral position and particle bands
will form, finally enabling a facile particle separation technique
using several outlets.
The main application of FFA consists of cell focusing and
continuous separation of particles from its liquid phase.
3338 | Lab Chip, 2013, 13, 3323–3346 This journal is  The Royal Society of Chemistry 2013
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Hence it is well adapted for plasma extraction. For instance, in
the device proposed by Nilsson et al.,179 non-diluted blood is
injected at 600 mL min21 in an 8-parallel channels separator.
Piezoceramic excitation is transverse so that cells align
themselves in the channel center, whereas plasma remains
in both lateral channels. Four devices are disposed in series
for a final purity close to 99%. Protein quality of plasma
extracted by acoustophoresis has been additionally validated
by the authors with the detection of PSA biomarker at clinically
relevant levels (Fig. 7A).31 Doria et al. recently presented a
novel acoustic plasma separation method,180 including the
integration of air–liquid cavity transducers. These new types of
transducers have the advantage of creating microstreams
within the flow patterns and swirling eddies where the RBCs
become aggregated. The authors reported a plasma extraction
rate of 10.6 nL s21. The plasma was allegedly pure at 90% or
more, although no characterisation technique was mentioned
in the article.
4.2.2. Electrical separation. Electrical forces have been
widely used to separate biological entities, such as DNA with
electrophoresis (uniform electric field allowing the separation
of charged particles) or various cell types with dielectrophor-
esis (DEP, non-uniform electric field allowing the separation of
uncharged particles).181 To date however, very few publications
relate the use of an electrical technique to extract plasma from
whole blood. Nakashima et al. developed a system relying on a
combination of capillary flow for fluid actuation and dielec-
trophoresis for the trapping of blood cells within a micro-
channel.182 When the cells are trapped under negative DEP
forces, the plasma flows by capillary action through lateral
channels to a plasma reservoir. The efficacy of the technique
depends on the amplitude and frequency of the AC current
used to trapped the cells. The separation reached 98% purity
(estimated using a hemocytometer) under the application of a
10 V voltage at a frequency of 1 MHz. The plasma yield is
relatively low (6%), with 300 nL of plasma extracted from 5 mL
of 1 : 9 diluted blood. A better yield was demonstrated, but at
the expense of the purity. No biological characterisation of the
extracted plasma was related.
Electro-osmotic flow was used by Jiang et al.183 to generate
liquid flow, as well as to extract a fraction of blood plasma.
Both of these functions were achieved by applying an electric
field across a main channel, and a weaker transversal electric
field across a series of bifurcations perpendicular to the main
channel (Fig. 7B). The main electric field generates the blood
flow across the main channel. At the same time, the transverse
field allows the actuation of plasma flow in the bifurcation
channels, but is not strong enough to pull the blood cells away
from their paths. In the actual experiment, blood was diluted
by 1 : 16 in PBS buffer, very few cells were seen entering the
plasma channels, and the plasma yield was reported to be as
high as 26%.
Although these techniques have to be optimized and fully
characterized, they may have some potential for highly
integrated plasma separation combined with in situ analysis.
Indeed, the electric field could be used to actuate the flow and
induce cell extraction from plasma as demonstrated in the
Fig. 7 Active blood plasma separation techniques in microfluidic format. (A) Acoustic plasma extraction. As blood is injected within themicrofluidic channel and through
a standingwave field, red cells experience acoustic forces and align themselves in the channel centre, while plasma can be collected continuously and efficiently near the
channel walls. Reprinted with permission from ref. 31. Copyright 2009 American Chemical Society. (B) Electrical plasma extraction. An electric field is applied across the
main channel and generates the blood flow. A transverse field allows the plasma flow towards the bifurcation channels but is not strong enough to generate red cell
motion. Adapted from ref. 183 with permission from IOP publishers.
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latest example, but also to separate entities (CNAs, proteins)
within the extracted plasma as well.
4.2.3. Magnetic separation. Diamagnetic particles such as
blood cells can be separated in high magnetic fields using
diamagnetic repulsion, a subject well documented,184 but
necessitating complex sample preparation.185 On the other
hand, red blood cells can be rendered paramagnetic in the
presence of additives or after their passage through a gas
permeable membrane. Magnetic separation of various blood
cells has been demonstrated on-chip,186–188 and the concept
has also been extended to the demonstration of blood cleaning
from microbial infections.189 Very few publications demon-
strate the use of magnetic fields for blood plasma separation
applications. In ref. 190, Takayasu et al. utilise a combination
of magnetic and gravitational force fields to extract the red
blood cells from blood after passing the blood through a gas-
permeable membrane, which allows the red blood cells to
reach their deoxygenated paramagnetic states. The system
should be further miniaturized as a microsystem, but never-
theless offers an interesting concept.
Magnetic separation of plasma from blood is theoretically
possible, but slightly impractical due to the additional
requirement of additives or membranes to render RBCs
paramagnetic. It is more suited for niche applications where
some cells might naturally be in a deoxygenated or para-
magnetic state. This is the case, for example, for fetal
nucleated red blood cells which are found to be naturally
paramagnetic in maternal circulation,191 or malaria-infected
red blood cells in the circulation of affected patients.192
4.3. Paper format
In the past 3 years (2009–2012) paper-based microfluidics has
been the centre of a flurry of research activities.193,194 Paper
has been widely used for lateral-flow assays, such as glucose
and lipid measurements,195 coagulation measurements196 or
pregnancy tests. But more recently, paper, a cost-effective,
easily sourced, and readily biodegradable material, has been
re-engineered to host a variety of integrated microfluidic
functions, including plasma extraction from blood. The
separation on paper-based format proposed in this section
differs from the dead-end filtration section (cf. section 4.1.2) as
in the latter, only the membrane is made of paper, not the
entire system.
Although paper is used in several devices to extract plasma
from blood, few examples showcase paper as the only
supporting format for the entire assay. In one example from
Yang et al., chromatography paper was not only used as a
substrate to agglutinate RBCs and extract plasma but also for
glucose metering applications (Fig. 8A).53 As chromatography
paper pores are large enough to let single RBCs flow through,
an agglutination strategy was developed to form RBC
aggregates and prevent them from flowing through the paper.
On the other hand, plasma flows by capillary action away from
the point where the finger-prick volume of blood has been
deposited. The plasma extracted was reported to have a
hematocrit value of 0.5 ¡ 0.2%, and was subsequently tested
for glucose concentration with a colorimetric assay elegantly
integrated in the paper structure (Fig. 8A). Glucose concentra-
tion was estimated to be within 10% of the concentration
obtained with a spectrophotometer, demonstrating the validity
of the device.
Another example of blood plasma separation coupled with a
direct assay on paper format was demonstrated by Songjaroen
et al.197 The device was manufactured using a wax-dipping
technique and featured a blood plasma separation membrane
combined with patterned Whatman nu1 paper. The design
comprises a separation chamber and two detection zones. 15
to 20 mL of blood with hematocrit varying between 24 to 55%
are deposited in the separation chamber, and within 2 min,
the plasma is extracted and enters by capillarity into the
detection zones. This technique did not require an agglutina-
tion strategy as in ref. 53. Microscopy observation was used to
check plasma purity, and no cells were found in the detection
zone. Following the plasma separation, a bromocresol green
colorimetric assay was used to detect the presence of albumin
in the chip detection zones. The chip assay resulted in similar
performance as the conventional method.
Whitesides’ group proposed a design where the plasma is
filtered vertically through the paper. The colorimetric detec-
tion of proteins related to liver functions (alkaline phospha-
tase (ALP) and AST) was integrated with plasma separation.34
For more convenience, the device was partially encapsulated in
plastic, protecting the sample from excessive evaporation. The
wax-printing technique employed allows hydrophobic barriers
to be patterned in the paper and defines hydrophilic zones for
the spotting of three independent assays. 15 mL of whole blood
were applied on top of the filter, and the plasma was checked
visually after 15 min. GX and GR filters from Pall were found to
be suitable for this application. Despite discrepancies in the
way the colorimetric assays were developed, the detection of
ALP, AST and BSA was successfully demonstrated with whole
blood samples.
While paper can be used conveniently to separate several
microlitres of blood such as finger-prick volumes, it rapidly
clogs and is unsuitable for larger volumes, limiting its use to
the analysis of highly concentrated analytes, such as glucose53
or abundant proteins.197 Nevertheless, it is expected that
researchers in the paper field will come up with several
analysis techniques compatible with low plasma volume,
which might in turn translate into a range of useful
commercial lateral flow diagnostic kits.
4.4. CD format
Research on miniaturised CD-based labs-on-a-chip started in
the 1970s, but really kicked-off in the early 2000s with the
founding of Gyros and several research labs, including (but
not limited to) Madou’s and Ducree’s. The CD-based format
allows neat sample preparation as well as analysis, and
therefore are good examples of lab-on-a-chip devices in terms
of functional integration. An excellent exhaustive review of the
subject is available.198,199 Taking full advantage of the
centrifugation aspects, this format is obviously well-suited
for blood plasma extraction and this has been demonstrated
in several publications. Plasma extraction in a CD-based
format relies on the centrifugal force forcing the heavy cellular
content towards the external edge of the CD, while the plasma
is siphoned out by various valving systems. The success of the
3340 | Lab Chip, 2013, 13, 3323–3346 This journal is  The Royal Society of Chemistry 2013
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plasma separation in CD format relies on these valving
systems, which have included passive siphoning,200 hydro-
phobic, capillary,201,202 or ferrowax microvalves.203
An early example of plasma extraction in a CD-format was
demonstrated by Abaxis Inc and allowed plasma extraction
from 40 mL of whole blood and subsequent glucose measure-
ment in less than 10 min.201 The turbidity and amount of
hemolysis were assessed photometrically, however this data
was not communicated. Later, Haeberle et al. demonstrated
the extraction of plasma from 5 mL of blood in less than 20
s.202 The plasma yield was 40%, with a residual hematocrit
level of 0.11% (Fig. 8B). No biological validation of the plasma
was presented at the time. A fully integrated immunoassay,
including plasma extraction, was demonstrated by Lee et al.203
This system was able to retrieve 50 mL of plasma out of 150 mL
of whole blood (33% yield) in less than a minute. It can be
noticed that the color of the plasma extracted is pink, which is
a sign of haemoglobin release. Whereas this was due to the use
of old blood or to the characteristics of the separation device
itself, it cannot be ascertained. Nevertheless, the subsequent
concentration measurements of the antigen and the antibody
of Hepatitis B virus were performed, and found to be within
14% of the conventional bench-top equivalent. The latest
example of plasma extraction on a CD platform was demon-
strated by Madou’s group.200 Plasma separation from a 2 mL
blood sample took 2.5 min and the authors claimed a plasma
purity superior to 99.9%, although no mention of the
characterisation technique was made. Looking at the pictures,
the color of the plasma was pink, reflecting the possibility of
hemolysis. Again, this could be due to the age of the blood, the
parameters used for the centrifugation, or the device design.
No associated biological assay was presented.
Protocols on the CD-based format are rapid, and the
fabrication of CD cartridges is simple and cost-effective.
Parallelization is enabled by having several similar chambers
within one CD cartridge. However, the technology is limited by
the use of numerous valves and the fact that the movement of
fluid from one chamber to another relies only on the
centrifugation speed. Despite these limitations, as noted by
the authors of the ‘‘Centrifugal Microfluidics’’ review, it is
surprising that no more commercial applications have been
released.198
5. Future directions of microscale blood
plasma separation
In the past five years (2008–2013), the LOC community has
been sensitive to the challenges posed by blood sample
preparation, and a high number of publications have demon-
strated the clinical utility of this ‘‘sample prep’’ in a vast
number of applications. This review has explored the
diversified range of analytes found in plasma, which are
attracting a growing interest for diagnostics and prognosis
purposes, such as cancer biomarkers, viruses or circulating
nucleic acids among others. As blood irrigates all our organs,
the number of analytes of interest will not cease to rise, and we
have yet to uncover diagnostic potential of even smaller
Fig. 8 Blood plasma extraction on paper and CD format. (A) Design of a microfluidic paper-based analytical device (mPAD) with integrated plasma extraction. Adapted
from ref. 53. Agglutinating antibodies and assay reagents are spotted on the mPAD. When a drop of whole blood is added on the device, RBCs react with agglutinating
antibodies and remain in the central zone. Plasmamigrates into the test zones and reacts with colorimetric assay reagents. (B) Plasma extraction on a CD format. Adapted
from ref. 202. Whole blood is first centrifugally metered (5 mL), flows out of the metering chamber into the drain channel, where plasma and cellular constituents are
separated along with centrifugation. Purified plasma is decanted into a separate reservoir while the cellular pellet is retained at the bottom of the decant chamber.
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Lab on a Chip Critical Review
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
4 
Ju
ly
 2
01
3.
 D
ow
nl
oa
de
d 
on
 0
4/
02
/2
01
4 
09
:5
6:
39
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
plasma molecules, such as microRNA for example. MicroRNAs
are short strands, less than 22 nucleotides, of non-coding RNA,
which may play a key role in gene regulation and present
therapeutic and diagnostic opportunities204 and, in particular,
in a number of cancers.205–207
In the field of plasma separation, three categories of sample
volumes are prominent: large volume samples (over 500 mL)
for transfusion, medium volume samples (0.5–50 mL) from
venous collection for multi-parameter blood analyses, and
small volume samples (y10 mL) from finger-pricks for specific
analyses. Due to the vast number of devices created and
developed by LOC researchers and engineers, microfluidic
solutions are capable of answering the needs of each of these
situations. For instance, sedimentation strategies and capillary
flow actuation lend themselves very well to the detection of
highly concentrated analytes in capillary volumes of blood,
such as glucose, some proteins and other metabolites, in
which case slow flow rates do not hinder performance. For
venous sample volumes, biomimetic hydrodynamic solutions
at relatively high flow rates are especially well suited, as well as
high-throughput active techniques like acoustophoresis, since
despite needing more equipment, transducers are relatively
easy to integrate. Some continuous solutions, such as inertial
microfluidics that can operate at extremely high flow rates
(mL–L min21), may even be applicable to transfusion-scale
volumes and plasmapheresis applications through the paral-
lelization of several base units. Clearly, there is no single
solution to solve all the challenges laid at the beginning of the
review, but there are a myriad of systems which perform best
for particular applications. Future solutions may lay in hybrid
technologies, which integrate two or more of these technolo-
gies to achieve high throughput as well as high purity.
Generally speaking, the transposition of commonly used
macro-scale technologies at the microscale, although tempt-
ing, has rarely been straightforward due to challenges such as
clogging issues for microfiltration or the creation of Dean
secondary flows in microchannels with curvature.
Biomimetism works best at the microscale, and the techniques
arising that exploit natural hemorheological phenomena, with
some modifications, are producing some of the best results in
microscale blood plasma separation.
Portability and ease of use are more than ever in the
designers’ mind, and sometimes lead to very unconventional
innovations, with the example of the egg-beater developed by
Wong et al. for hand-powered plasma extraction.208 By its
simplicity and the familiarity of its actuation device, this
example stands out in the blood plasma separation literature
panorama (Fig. 9). In this example and several others over the
past three years, ease of use, portability and cost-effectiveness
come first, and these devices have been specifically designed
for resource-poor settings. Paper devices and designs with
capillary flow actuation also address the issue of equipment
limitations relative to the operating environment, however
they remain limited to concentrated analytes. On the other
hand, portability may not be the only criteria of interest. Some
devices solve other challenges, such as the collection of small
volumes of plasma (less than a vacutainer tube) over a large
period of time (.4 h), as with the cross-flow filtration
technique applied to the cardiopulmonary bypass machin-
ery.46
The importance of clinical validation was largely acknowl-
edged by research communities in the past five years, and
more and more articles demonstrate some sort of clinical
validation, either through the demonstration of classical
biological assays (such as ELISA or PCR), or in specific clinical
settings through inter-disciplinary collaboration with clini-
cians. Furthermore, the failure of some lab-on-a-chip technol-
ogies may be attributed to the lack of clinician involvement,
failing to leverage industrial interest, and subsequently having
a lack of funds for commercialisation purposes. Clinicians and
their staff are the end-users of most of these sample
preparation systems and are thus best placed to define their
need for new equipment, capable of reducing the cost of
analysis or speeding or refining the acquisition of results.
Furthermore, collaboration engineering is the best approach
to raise awareness about real clinical needs and challenges,
Fig. 9 Plasma extraction using an egg-beater. (A) Approximately 100 mL of blood
sample is collected in a polyethylene (PE) piece of tubing using a rubber bulb. Blood
can also be drawn from a finger-prick. (B) The tubing is sealed at both ends and
attached at the end of one paddle on the egg-beater. After 8 min of manual spinning
at approximately 1200 rpm, the tubing is detached from the egg-beater and cut
at the interface between plasma and supernatant. (C) The plasma is put in contact
with the paper,which absorbs the plasma in the colorimetric cholesterol assay regions.
(D) The puritywas found to be close to 100% (50 000 cells remaining permL). Adapted
from ref. 208.
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and consequently the key to developing potentially marketable
technologies usable in clinical settings. Collaboration forces
engineers to think innovatively by always adapting themselves
to novel situations and should be the way forward for the LOC
community.
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